Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests Illustration of a semaglutide peptide (blue) bound to its target glucagon-like peptide-1 (GLP-1, light pink).

New research has found that GLP-1 drugs can substantially reduce the risk of obesity-related cancers — and they’re more ...

The data showed patients who took GLP-1 drugs had a much lower risk of developing cancer than those who took DDP-4s.

Mounjaro, Ozempic and other fat-melting injections ... no medications have been proven to lower the cancer risk associated with obesity. 'Our study begins to fill that gap by evaluating GLP ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.

Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Weight loss jabs could reduce the risk of up to 14 types of cancer, new research has found. Mounjaro, Ozempic and other ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

Weight-loss injections could cut the risk of cancer by almost half, research suggests. Researchers analysed the health ...

Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol addiction. One ...